IN2014DN06117A - - Google Patents
Info
- Publication number
- IN2014DN06117A IN2014DN06117A IN6117DEN2014A IN2014DN06117A IN 2014DN06117 A IN2014DN06117 A IN 2014DN06117A IN 6117DEN2014 A IN6117DEN2014 A IN 6117DEN2014A IN 2014DN06117 A IN2014DN06117 A IN 2014DN06117A
- Authority
- IN
- India
- Prior art keywords
- buprenorphine
- methods
- delivery device
- environment
- buffered
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Provided herein are methods for treating chronic pain by administering low doses of buprenorphine twice daily (or once daily) via a trarismucosal drug delivery device. The methods and devices efficiently treat chronic pain without significant side effects. In one embodiment the buprenorphine delivery device comprises a bioerodable mucoadhesive layer comprising a therapeutically effective amount of buprenorphine disposed in a buffered polymeric diffusion environment wherein the polymeric diffusion environment is a buffered environment having a pH of between about 4 and about 6.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161578755P | 2011-12-21 | 2011-12-21 | |
| PCT/US2012/071330 WO2013096811A2 (en) | 2011-12-21 | 2012-12-21 | Transmucosal drug delivery devices for use in chronic pain relief |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN06117A true IN2014DN06117A (en) | 2015-08-14 |
Family
ID=48669710
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN6117DEN2014 IN2014DN06117A (en) | 2011-12-21 | 2012-12-21 |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP2793870A4 (en) |
| JP (1) | JP6255349B2 (en) |
| KR (4) | KR20210003313A (en) |
| CN (2) | CN104125828A (en) |
| AU (4) | AU2012358308A1 (en) |
| BR (1) | BR112014015329A2 (en) |
| CA (1) | CA2859859A1 (en) |
| EA (2) | EA201992762A1 (en) |
| HK (1) | HK1203365A1 (en) |
| IL (2) | IL233075A0 (en) |
| IN (1) | IN2014DN06117A (en) |
| MX (2) | MX362217B (en) |
| SG (3) | SG10201710667YA (en) |
| UA (1) | UA118540C2 (en) |
| WO (1) | WO2013096811A2 (en) |
| ZA (1) | ZA201804381B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210251983A1 (en) * | 2020-02-13 | 2021-08-19 | Biodelivery Sciences International, Inc. | Methods of treatment with buprenorphine |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5800832A (en) | 1996-10-18 | 1998-09-01 | Virotex Corporation | Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces |
| DE19652188C2 (en) * | 1996-12-16 | 2002-02-14 | Lohmann Therapie Syst Lts | Flat drug preparation for application and release of buprenorphine or a pharmacologically comparable substance in the oral cavity and process for its preparation |
| US5968547A (en) * | 1997-02-24 | 1999-10-19 | Euro-Celtique, S.A. | Method of providing sustained analgesia with buprenorphine |
| DE19960154A1 (en) * | 1999-12-14 | 2001-07-12 | Lohmann Therapie Syst Lts | Flat pharmaceutical preparation for transmucosal administration of oxycodone or a comparable active ingredient in the oral cavity, for use in pain therapy and addiction therapy |
| PT1255547E (en) * | 2000-02-08 | 2008-11-24 | Euro Celtique Sa | Controlled-release compositions containing opioid agonist and antagonist |
| JP4292570B2 (en) | 2001-04-27 | 2009-07-08 | 味の素株式会社 | N-substituted pyrazole-O-glycoside derivatives and therapeutic agents for diabetes containing them |
| US20110033542A1 (en) | 2009-08-07 | 2011-02-10 | Monosol Rx, Llc | Sublingual and buccal film compositions |
| DE102005007859A1 (en) * | 2005-02-21 | 2006-08-24 | Lts Lohmann Therapie-Systeme Ag | Procedures for a combination drug treatment, as well as suitable drug combinations |
| US20060281775A1 (en) * | 2005-06-14 | 2006-12-14 | Applied Pharmacy Services, Inc. | Two-component pharmaceutical composition for the treatment of pain |
| EP1968539A2 (en) * | 2005-12-13 | 2008-09-17 | Biodelivery Sciences International, Inc. | Abuse resistant transmucosal drug delivery device |
| US8734519B2 (en) | 2006-04-12 | 2014-05-27 | Spinalmotion, Inc. | Posterior spinal device and method |
| EP3067044B1 (en) * | 2006-07-21 | 2019-03-27 | BioDelivery Sciences International, Inc. | Transmucosal delivery devices with enhanced uptake |
| EP1897543A1 (en) * | 2006-08-30 | 2008-03-12 | Euro-Celtique S.A. | Buprenorphine- wafer for drug substitution therapy |
| GB0620661D0 (en) * | 2006-10-18 | 2006-11-29 | Pharmasol Ltd | Novel compounds |
| US20090270438A1 (en) * | 2006-10-18 | 2009-10-29 | Clive Booles | Novel compositions and formulations |
| GB2447016A (en) * | 2007-03-01 | 2008-09-03 | Reckitt Benckiser Healthcare | Buprenorphine/naloxone compositions |
| EP2293751B1 (en) * | 2008-06-23 | 2018-01-10 | BioDelivery Sciences International, Inc. | Multidirectional mucosal delivery devices and methods of use |
| US8475832B2 (en) | 2009-08-07 | 2013-07-02 | Rb Pharmaceuticals Limited | Sublingual and buccal film compositions |
-
2012
- 2012-12-21 SG SG10201710667YA patent/SG10201710667YA/en unknown
- 2012-12-21 KR KR1020207038099A patent/KR20210003313A/en not_active Application Discontinuation
- 2012-12-21 KR KR1020197027379A patent/KR20190110628A/en active Application Filing
- 2012-12-21 EP EP12860757.9A patent/EP2793870A4/en active Pending
- 2012-12-21 EA EA201992762A patent/EA201992762A1/en unknown
- 2012-12-21 IN IN6117DEN2014 patent/IN2014DN06117A/en unknown
- 2012-12-21 AU AU2012358308A patent/AU2012358308A1/en not_active Abandoned
- 2012-12-21 WO PCT/US2012/071330 patent/WO2013096811A2/en active Application Filing
- 2012-12-21 CN CN201280070389.6A patent/CN104125828A/en active Pending
- 2012-12-21 KR KR1020147020237A patent/KR102026321B1/en active IP Right Grant
- 2012-12-21 BR BR112014015329A patent/BR112014015329A2/en not_active Application Discontinuation
- 2012-12-21 EA EA201491046A patent/EA034529B1/en unknown
- 2012-12-21 KR KR1020227011298A patent/KR20220047889A/en not_active Application Discontinuation
- 2012-12-21 SG SG10202012743WA patent/SG10202012743WA/en unknown
- 2012-12-21 CN CN201910440007.8A patent/CN110123792A/en active Pending
- 2012-12-21 JP JP2014548962A patent/JP6255349B2/en active Active
- 2012-12-21 UA UAA201406826A patent/UA118540C2/en unknown
- 2012-12-21 CA CA2859859A patent/CA2859859A1/en not_active Abandoned
- 2012-12-21 SG SG11201403075XA patent/SG11201403075XA/en unknown
- 2012-12-21 MX MX2014007350A patent/MX362217B/en active IP Right Grant
-
2014
- 2014-06-11 IL IL233075A patent/IL233075A0/en unknown
- 2014-06-18 MX MX2021012154A patent/MX2021012154A/en unknown
-
2015
- 2015-04-22 HK HK15103881.9A patent/HK1203365A1/en unknown
-
2017
- 2017-11-09 AU AU2017258916A patent/AU2017258916B2/en active Active
-
2018
- 2018-06-29 ZA ZA2018/04381A patent/ZA201804381B/en unknown
-
2019
- 2019-04-15 AU AU2019202602A patent/AU2019202602A1/en not_active Abandoned
-
2021
- 2021-04-01 AU AU2021202042A patent/AU2021202042A1/en active Pending
- 2021-07-23 IL IL285091A patent/IL285091A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009000745A (en) | Transmucosal delivery devices with enhanced uptake. | |
| PH12015500246A1 (en) | Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor | |
| WO2013024282A3 (en) | Inhibitor or down- regulator of the expression of one or both of tbk1 ikk-epsilon for use in the treatment of pi3kinase dependent cancer | |
| WO2015066647A3 (en) | Ionic liquids for transdermal drug delivery | |
| MX342001B (en) | Treatment of lupus arthritis using laquinimod. | |
| MX2014001873A (en) | Abuse-resistant mucoadhesive devices for delivery of buprenorphine. | |
| MX2012014521A (en) | Use of levocetirizine and montelukast in the treatment of influenza, common cold and inflammation. | |
| MX2017017138A (en) | Targeted conjugates of ksp inhibitors. | |
| WO2014153385A3 (en) | Methods of treating metabolic disorders | |
| MX367070B (en) | Drug delivery systems and methods for treatment of prostate disease comprising gemicitabine. | |
| WO2018102261A3 (en) | Boronic derivatives hydroxamates as anticancer agents | |
| MX2015010296A (en) | Treatment of multiple sclerosis with laquinimod. | |
| WO2013083826A3 (en) | Glp-1 agonists | |
| IN2014DN06117A (en) | ||
| UA106131C2 (en) | Prophylactic or therapeutic agent for diseases associated with pains in urinary organs | |
| MX2010006724A (en) | Therapeutic regimens for the treatment of immunoinflammatory disorders. | |
| UA115250C2 (en) | Pharmaceutical combinations | |
| MX2010013790A (en) | Compostions and methods for treating corneal inflammation. | |
| CL2012000488A1 (en) | Use of charcoal to treat an overdose of dabigatran etexilate. | |
| NZ724912A (en) | Transmucosal drug delivery devices for use in chronic pain relief | |
| MX2011006758A (en) | Pharmaceutical composition for use against inflammation and pain. | |
| MX2010004457A (en) | Idarubicin for the treatment of lymphoma in a dog. | |
| UA33217U (en) | Method for treating chronic dermatosis | |
| UA96455C2 (en) | Transmucosal delivery devices with enhanced uptake | |
| UA87982U (en) | Method for conservative treatment of ovaricovaricocele |